Swedish Orphan Biovitrum Income from Continuous Operations 2019-2025 | BIOVF

Swedish Orphan Biovitrum income from continuous operations for the twelve months ending June 30, 2025 was $0.417B, a 106.49% increase year-over-year.

  • Swedish Orphan Biovitrum annual income from continuous operations for 2024 was $0.367B, a 61.6% increase from 2023.
  • Swedish Orphan Biovitrum annual income from continuous operations for 2023 was $0.227B, a 13.14% decline from 2022.
  • Swedish Orphan Biovitrum annual income from continuous operations for 2022 was $0.261B, a 16.31% decline from 2021.

Swedish Orphan Biovitrum Income from Continuous Operations 2019-2025 | BIOVF

  • Swedish Orphan Biovitrum annual income from continuous operations for 2024 was $0.367B, a 61.6% increase from 2023.
  • Swedish Orphan Biovitrum annual income from continuous operations for 2023 was $0.227B, a 13.14% decline from 2022.
  • Swedish Orphan Biovitrum annual income from continuous operations for 2022 was $0.261B, a 16.31% decline from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$229.7B
Amgen (AMGN)$153.5B
Gilead Sciences (GILD)$149.5B
Vertex Pharmaceuticals (VRTX)$96B
Bristol Myers Squibb (BMY)$93.5B
CSL (CSLLY)$83.2B
GSK (GSK)$76.9B
Regeneron Pharmaceuticals (REGN)$57.9B
Alnylam Pharmaceuticals (ALNY)$57B
Argenex SE (ARGX)$39.1B
BioNTech SE (BNTX)$26.3B
Insmed (INSM)$23.9B
Royalty Pharma (RPRX)$20.3B
Biogen (BIIB)$18.8B
Incyte (INCY)$15.5B
Illumina (ILMN)$14.6B
Genmab (GNMSF)$14.3B
Genmab (GMAB)$13.5B
Ascendis Pharma (ASND)$12B
BioMarin Pharmaceutical (BMRN)$10.9B
QIAGEN (QGEN)$10.7B
Exelixis (EXEL)$10.1B
Moderna (MRNA)$9.9B
Verona Pharma American Depositary Share (VRNA)$9B
Blueprint Medicines (BPMC)$8.3B
Bio-Techne Corp (TECH)$7.9B
Halozyme Therapeutics (HALO)$7.7B
Exact Sciences (EXAS)$7.7B
Roivant Sciences (ROIV)$7.6B
Guardant Health (GH)$6.8B